Technical Analysis for FGEN - FibroGen, Inc

Grade Last Price % Change Price Change
grade D 36.82 0.66% 0.24
FGEN closed up 0.66 percent on Friday, May 22, 2020, on 41 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Flat
Historical FGEN trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Fell Below 20 DMA Bearish 0.66%
Crossed Above 20 DMA Bullish -2.05%
MACD Bullish Centerline Cross Bullish -2.05%
180 Bullish Setup Bullish Swing Setup -2.05%
MACD Bearish Centerline Cross Bearish 3.89%
20 DMA Resistance Bearish 0.79%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 2.02%
Narrow Range Bar Range Contraction 2.02%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

FibroGen, Inc. operates as a research-based biopharmaceutical company in the United States. The company focuses on the discovery, development, and commercialization of therapeutic agents to treat serious unmet medical needs. The company develops roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019, a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. It also focuses on use of the proprietary type III recombinant human collagens in its biosynthetic corneal implant product candidate, FG-5200 for the treatment of corneal blindness. The company was incorporated in 1993 and is headquartered in San Francisco, California.
Biotechnology Biopharmaceutical Life Sciences Chronic Kidney Disease Pancreatic Cancer Anemia Idiopathic Pulmonary Fibrosis Hypoxia Inducible Factors Liver Fibrosis Research Based Biopharmaceutical Treatment Of Idiopathic Pulmonary Fibrosis

Is FGEN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 48.95
52 Week Low 22.65
Average Volume 702,131
200-Day Moving Average 40.04
50-Day Moving Average 34.85
20-Day Moving Average 37.08
10-Day Moving Average 36.87
Average True Range 2.20
ADX 11.75
+DI 23.74
-DI 19.26
Chandelier Exit (Long, 3 ATRs ) 34.64
Chandelier Exit (Short, 3 ATRs ) 39.76
Upper Bollinger Band 39.89
Lower Bollinger Band 34.26
Percent B (%b) 0.45
BandWidth 15.18
MACD Line 0.01
MACD Signal Line 0.12
MACD Histogram -0.1102
Fundamentals Value
Market Cap 2.62 Billion
Num Shares 71.2 Million
EPS -1.92
Price-to-Earnings (P/E) Ratio -19.18
Price-to-Sales 32.73
Price-to-Book 16.72
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 38.26
Resistance 3 (R3) 38.13 37.52 38.02
Resistance 2 (R2) 37.52 37.15 37.59 37.94
Resistance 1 (R1) 37.17 36.93 37.35 37.30 37.86
Pivot Point 36.56 36.56 36.65 36.63 36.56
Support 1 (S1) 36.21 36.19 36.39 36.34 35.78
Support 2 (S2) 35.60 35.97 35.67 35.70
Support 3 (S3) 35.25 35.60 35.62
Support 4 (S4) 35.38